Faculty Bibliography

OBJECTIVES/OBJECTIVE:To determine the rate at which abstracts accepted for the Orthopedic Trauma Association (OTA) Annual Meeting from 2019 to 2024 utilized the Fracture-related Infection (FRI) Consensus Group's definition for infection. METHODS:Data Sources: The data sources for this study included the Orthopedic Trauma Association (OTA) Annual Meeting Programs from 2019-2024 and the "abstract search" portion of OTA Website. STUDY SELECTION/METHODS:All podium and poster abstract presentations that utilized keywords for infection ("fracture-related infection," "infection," or "SSI") in the title. DATA EXTRACTION/METHODS:All abstracts were reviewed, and grouped into one of the four following categories based on the methodologic descriptors used to define infection characteristics: 1) Utilized Consensus Group Definition, 2) Utilized CDC Definition [deep, superficial, organ/space, or SSI terminology], 3) Utilized an Author Specific Definition, 4) Did Not Utilize Any Definition. DATA SYNTHESIS/RESULTS:Univariate statistics were conducted to determine yearly and overall percentages of abstracts that utilized the Consensus Group's definition as compared to the other 3 definition categories. Bivariate analysis was performed to determine if the use of Consensus Group's definition varied from 2019-2024. RESULTS:52 podium abstracts and 59 poster abstracts were included. Among the podium abstracts, 4 (7.7%) utilized the Consensus Group's definition of FRI, 37 (71.2%) utilized language from the CDC definition, 4 (7.7%) used an author specific definition, and 7 (13.5%) abstracts did not utilize any definition of descriptors of infection. Poster abstracts demonstrated similar utilization of methodical infection descriptors, as 5 (8.5%) utilized the Consensus Group's definition of FRI. The number of abstracts that utilized the Consensus Group's Definition did not vary from 2019-2024 (p=0.952 for podiums, p=0.451 for posters). CONCLUSIONS:Adoption of the FRI Consensus Group's definition among accepted OTA 2019-2024 Annual Meeting abstracts was low. LEVEL OF EVIDENCE/METHODS:IV.

BACKGROUND:Inferring risk for malignant transformation (MT) in patients with lesions diagnosed as mild or moderate oral epithelial dysplasia (low-grade OED) remains challenging. We developed two models assessing the risk of progression to high-grade OED (severe dysplasia or carcinoma in situ) or OSCC in patients with low-grade OED lesions. METHODS:We included demographic, risk habit and clinical data from participants with low-grade OED lesions enrolled in the BC Oral Cancer Prevention Program's Oral Cancer Prediction Longitudinal study. Cox proportional hazard models were fit to estimate the effects of anatomic site and toluidine blue findings and adjusted for confounders, as both are associated with MT in the literature but without a North American-specific cohort analysis. Our primary model included both variables of interest. A secondary model included only anatomic site since toluidine blue is not in widespread use. RESULTS:Five hundred and thirty-four participants with 605 lesions met final inclusion criteria, with 339 mild and 266 moderate OED at baseline. In the primary model, lesions at a high-risk anatomic site or with positive toluidine blue staining were associated with a 2.6 and 2.4-fold increased risk of progression, respectively. In the second model that did not incorporate toluidine blue, high-risk anatomic site remained a highly associated risk factor (2.7-fold increased risk of progression). CONCLUSION/CONCLUSIONS:Lesion anatomic site is associated with higher risk of MT for the general practitioner, while a specialist with access to toluidine blue results can assume additional risk associated with positive staining. These models may inform decisions for surveillance and intervention for OED.

OBJECTIVE:To assess the environmental impact of magnetic resonance (MR) and computed tomography (CT) imaging using life cycle assessment (LCA), focusing on energy use, resource consumption, and emissions. METHODS:This ISO 14040-guided LCA-based study focused on MRI and CT services, including the production and use of three MRI and four CT scanners, at a quaternary care 800-bed academic medical center in the Southeastern USA over a one-year period. Data were collected through direct observation, record review, staff interviews, and energy metering. Environmental impacts were assessed using SimaPro 9.3.0.2 and the Ecoinvent v3.8 database. RESULTS:MRI and CT services at this site generate an estimated 221 and 108 tons of CO2e per year, respectively. This is equivalent to the emissions of 52 (MRI) and 25 (CT) cars driven annually. Energy consumption accounted for the largest portion of emissions (58% for MRI, 33% for CT), followed by disposable supplies (26% for MRI, 16% for CT), capital equipment production (7% for MRI, 13% for CT), and linens (4% for MRI, 11% for CT). Switching to solar photovoltaic electricity could reduce total MRI emissions by 70% and CT emissions by 40%, increasing the relative impacts of scanner production, disposable supplies, and linens. DISCUSSION/CONCLUSIONS:This study highlights the significant environmental impact of MRI and CT services, particularly energy consumption. Renewable energy sources, such as solar photovoltaics, offer the greatest potential for mitigating the environmental footprint. Additional strategies include optimizing scanner utilization, adopting reusable or reprocessable supplies, and embracing circular business practices such as circular manufacturing and extending the lifespan of capital equipment.

OBJECTIVE:Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histological features and treatment response. METHODS:SLE patients (n=268) undergoing clinically indicated kidney biopsies (urine protein/creatinine ratio [UPCR] > 0.5) were recruited through the AMP RA/SLE network. Serum was collected at biopsy and 3-, 6-, and 12-months post-biopsy, alongside samples from 22 healthy controls. Concentrations of 66 immune mediators were quantified using xMAP multiplex assays, and TNF-α converting enzyme (TACE) measured by ELISA. Seven mediators with >95% values below detection limits were excluded from analyses. Bootstrapped LASSO regression identified proliferative LN (class III/IV+V) predictors from baseline mediators. Associations with 12-month treatment response (complete/partial vs. no response) were tested using 3-month changes in LASSO-selected mediators and UPCR via logistic regression. Molecular clustering of mediator profiles was performed to identify LN subgroups. RESULTS:Proliferative LN patients (class [III or IV] + V; n=160) displayed a distinct mediator profile compared to non-proliferative LN (class I/II/V; n=96). LASSO regression identified 20 mediators predictive of proliferative LN (AUC, 0.82; 95% CI, 0.81-0.91), including elevated syndecan-1, TNFRI, TNFRII, and VCAM-1, as well as decreased CCL3/MIP-1α, CD40L, and IL-5 levels. Among proliferative LN patients, 3-month reductions in syndecan-1 and VCAM-1, mediators associated with intrarenal LN activity and/or chronicity, predicted 12-month treatment response. A model incorporating these reductions and a decline in UPCR predicted treatment response in proliferative LN (0.90; 95% CI, 0.82-0.98). Molecular clustering revealed 4 distinct LN subgroups with unique soluble mediator signatures and clinical features, not captured by histology alone. CONCLUSION/CONCLUSIONS:Serum soluble mediators, particularly syndecan-1 and VCAM-1, reflect LN histological activity and early decreases predict treatment response, supporting their potential utility as noninvasive longitudinal biomarkers. The substantial heterogeneity within LN highlights the potential for biomarker-guided reclassification to advance precision medicine approaches.

PURPOSE/OBJECTIVE:To estimate economic and environmental reduction potential of iodinated contrast media (ICM) saving strategies, by examining supply chain data (from iodine extraction through administration) to inform a decision-making framework which can be tailored to local institutional priorities. METHODS:A 100 mL polymer vial of ICM was set as the standard reference case (SRC) for baseline comparison. To evaluate cost and emissions impacts, four ICM reduction strategies were modeled relative to this SRC baseline: vial optimization, hardware or software (AI-enabled) dose reduction, and multi-dose vial/injector systems. This analysis was then translated into a decision-making framework for radiologists to compare ICM strategies by cost, emissions, and operational feasibility. RESULTS:The supply chain life cycle of a 100 mL iodinated contrast vial produces 1,029 g CO2e, primarily from iodine extraction and clinical use. ICM-saving strategies varied widely in emissions reduction, ranging from 12%-50% nationally. Economically a 125% tariff could inflate national ICM-related costs to $11.9B, the ICM reduction strategy of AI-enhanced ICM systems could lower this expenditure to $2.7B. Institutional analysis reveals that the ICM savings from high-capital upfront investment strategies can offset their initial investment, highlighting important trade-offs for implementation decision-making. CONCLUSION/CONCLUSIONS:ICM is a major and modifiable contributor to healthcare carbon emissions. Depending on the utilized ICM-reduction strategy, emissions can be reduced by up to 53% and ICM-related costs by up to 50%. To guide implementation, we developed a decision-making framework that categorizes strategies based on environmental benefit, cost, and operational feasibility, enabling radiology leaders to align sustainability goals with institutional priorities.

OBJECTIVES/OBJECTIVE:To describe the distribution of laboratory values for nonstandard inflammatory and cardiac biomarkers in otherwise healthy children presenting to the pediatric emergency department (PED) with fever and viral or nonspecific illness. METHODS:Single-center retrospective study of otherwise healthy children 3 months to 20 years presenting to the PED with fever and had a laboratory evaluation for multisystem inflammatory syndrome in children (MIS-C) between April 15, 2020 and January 24, 2022. All patients had NT-pro-b-natriuretic peptide (NT-proBNP) or troponin obtained (as part of an institutional pathway for MIS-C evaluation) during this period. Children with comorbidities, MIS-C, Kawasaki disease, myocarditis, or definitive non-viral illness were excluded. We summarized d-dimer, ferritin, troponin, and NT-proBNP distributions using descriptive statistics. One-way analysis of variance tested for differences among 3 disease categories: non-SARS-CoV-2 viral illness, fever not otherwise specified (NOS), and SARS-CoV-2 infection. Outlier values were identified as three times the interquartile range above the third quartile on box-and-whisker plots. RESULTS:Of 134 eligible patients, 50, 65, and 19 were categorized as non-SARS-CoV-2 viral illness, fever NOS, and SARS-CoV-2 positive illness, respectively. Median age was 2 years. Median fever duration was 4 days, with 124/134 (93%) described as well-appearing and 112/134 (84%) discharged home. The median values for all biomarkers were within institutional laboratory reference ranges, with all distributions skewed to lower values, and without statistically significant differences between disease categories (P > 0.05). D-dimer values were above the institutional reference range in 43/97 (44%), ferritin was above the reference range in 24/114 (21%), NT-proBNP was above the reference range in 26/123 (21%), and troponin levels were outside the range in 4/123 (3%). Thirteen patients had extreme outlier values. CONCLUSIONS:Otherwise healthy children presenting to the PED with a fever and viral or nonspecific illnesses may frequently have elevated serum d-dimer, ferritin, and NT-proBNP above institutional reference ranges. Troponin elevation was infrequent.